These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15749627)

  • 1. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.
    Woo TC; Choo R; Jamieson M; Chander S; Vieth R
    Nutr Cancer; 2005; 51(1):32-6. PubMed ID: 15749627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.
    Beer TM; Lemmon D; Lowe BA; Henner WD
    Cancer; 2003 Mar; 97(5):1217-24. PubMed ID: 12599228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
    Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):983-9. PubMed ID: 19409726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
    Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.
    Goluboff ET; Prager D; Rukstalis D; Giantonio B; Madorsky M; Barken I; Weinstein IB; Partin AW; Olsson CA;
    J Urol; 2001 Sep; 166(3):882-6. PubMed ID: 11490238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
    J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.
    Neuhof D; Hentschel T; Bischof M; Sroka-Perez G; Hohenfellner M; Debus J
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1411-7. PubMed ID: 17275204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
    Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
    BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
    Pruthi RS; Johnstone I; Tu IP; Stamey TA
    Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
    Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):407-12. PubMed ID: 19211197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen (PSA) in the monitoring of prostate cancer after radical prostatectomy and external beam radiation.
    Schaefer U; Witt F; Schueller P; Micke O; Willich N
    Anticancer Res; 2000; 20(6D):4989-92. PubMed ID: 11326654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.
    Yu H; Diamandis EP; Wong PY; Nam R; Trachtenberg J
    J Urol; 1997 Mar; 157(3):913-8. PubMed ID: 9072598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.